GlaxoSmithKline‘s (NYSE:GSK) interest in tiny neural implants is stronger than ever, even amid declining earnings and flopped drug candidates that have turned CEO Andrew Witty into a lame duck who will step aside in 2017. Despite the turmoil, the British pharma giant is investing $50 million in so-called bioelectronics via Action Potential Ventures, aiming to fund companies […]
Propeller Health said today it inked a deal with GlaxoSmithKline (NYSE:GSK) to develop a sensor for GSK’s Ellipta dry powder inhaler. Through the non-exclusive agreement, the 1st between the 2 companies, Propeller will develop and manufacture a custom sensor for the Ellipta inhaler for use in clinical studies of the device used to treat asthma and […]
SetPoint said today it raised $15 million in an extension of its Series C round of equity financing and added GlaxoSmithKline (NYSE:GSK)’s Action Potential Venture Capital to its list of investors. The funds from the round are slated to support clinical trials of the company’s bioelectronic therapy for treating rheumatoid arthritis and Crohn’s Disease and […]
Wright Medical Group Inc. (NSDQ:WMGI) announced a surprise shakeup of its executive team today, firing its chief technology officer and accepting the resignation of CEO Gary Henley.
The Arlington, Tenn.-based maker of orthopedic devices for the foot and ankle market said in a regulatory filing that Henley resigned prior to a board meeting yesterday.
The deal gives the British pharma giant — stung by recent problems with its Avandia diabetes drug — exclusive rights to market and sell Bedford, Mass.-based Insulet’s OmniPod system north of the border.